Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

75
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

0
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

1

Information Journal Paper

Title

MEROPENEM VERSUS CEFTAZIDIME IN THE TREATMENT OF CANCER PATIENTS WITH FEBRILE NEUTROPENIA: A RANDOMIZED, DOUBLE-BLIND TRIAL

Pages

  3690-3698

Keywords

Not Registered.

Abstract

Cites

References

  • No record.
  • Cite

    APA: Copy

    FELD, R., DEPAUW, B., & BERMAN, S.. (2000). MEROPENEM VERSUS CEFTAZIDIME IN THE TREATMENT OF CANCER PATIENTS WITH FEBRILE NEUTROPENIA: A RANDOMIZED, DOUBLE-BLIND TRIAL. JOURNAL OF CLINICAL ONCOLOGY, 18(21), 3690-3698. SID. https://sid.ir/paper/652823/en

    Vancouver: Copy

    FELD R., DEPAUW B., BERMAN S.. MEROPENEM VERSUS CEFTAZIDIME IN THE TREATMENT OF CANCER PATIENTS WITH FEBRILE NEUTROPENIA: A RANDOMIZED, DOUBLE-BLIND TRIAL. JOURNAL OF CLINICAL ONCOLOGY[Internet]. 2000;18(21):3690-3698. Available from: https://sid.ir/paper/652823/en

    IEEE: Copy

    R. FELD, B. DEPAUW, and S. BERMAN, “MEROPENEM VERSUS CEFTAZIDIME IN THE TREATMENT OF CANCER PATIENTS WITH FEBRILE NEUTROPENIA: A RANDOMIZED, DOUBLE-BLIND TRIAL,” JOURNAL OF CLINICAL ONCOLOGY, vol. 18, no. 21, pp. 3690–3698, 2000, [Online]. Available: https://sid.ir/paper/652823/en

    Related Journal Papers

  • No record.
  • Related Seminar Papers

  • No record.
  • Related Plans

  • No record.
  • Recommended Workshops






    مرکز اطلاعات علمی SID
    strs
    دانشگاه امام حسین
    بنیاد ملی بازیهای رایانه ای
    کلید پژوه
    ایران سرچ
    ایران سرچ
    File Not Exists.
    Move to top